Pfizer Corporation

Wyeth

Medimmune Limited

Laird Bloom

Davinder Gill

Deborah A Young

Yulia Vugmeyster

Leslie Sydnor Johnson

Paul A Moore

Lioudmila Tchistiakova

William Brady

James Reasoner Apgar

Lidia Mosyak

David C Lowe

Viia Valge-Archer

Margot O'Toole

Karl Henry Nocka

Adam Reid Root

Matthew Allister Lambert

Chad Michael May

Maya Arai

Karissa K Adkins

Amy Arlene Weaver

Sadhana Jain

Mark A Farmer

Heath M Guay

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.

Anti-IL-33 antibodies, compositions, methods and uses thereof

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.

Bispecific heterodimeric diabodies and uses thereof

The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.

Methods of treatment utilizing binding proteins of the interleukin-21 receptor

The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Interleukin-21 receptor binding proteins

Growing community of inventors

Needham, MA, United States of America

Laird Bloom